Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent
Litigation
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Aurobindo Pharma
Ltd., resolving patent litigation brought in response to Aurobindo Pharma’s abbreviated new drug application (ANDA) seeking
approval to market a generic version of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents. The
settlement with Aurobindo is the second patent infringement settlement the companies have reached with respect to LINZESS.
Pursuant to the terms of the settlement, Ironwood and Allergan will grant Aurobindo Pharma a license to market a generic version
of LINZESS in the United States beginning on August 5, 2030 (subject to U.S. FDA approval), unless certain limited circumstances,
customary for settlement agreements of this nature, occur. As a result of the settlement, all ongoing Hatch-Waxman litigation
between the companies and Aurobindo Pharma regarding LINZESS patents will be dismissed. Additional details regarding the settlement
were not disclosed.
“LINZESS is the leading branded treatment prescribed in the U.S. for adult sufferers of irritable bowel syndrome with
constipation or chronic idiopathic constipation, with more than 10 million prescriptions filled,” said Bill Meury, Executive Vice
President and Chief Commercial Officer, Allergan. “We are pleased to have resolved the patent litigation with Aurobindo Pharma.
Allergan and Ironwood continue to invest in the LINZESS franchise and to be confident in the product’s market leadership.”
As required by law, the companies will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S.
Department of Justice for review.
Patent infringement litigations brought by the companies against other parties who have submitted ANDAs to the U.S. FDA seeking
approval to market generic versions of LINZESS remain pending in the U.S. District Court for the District of Delaware, where the
earliest scheduled trial date is June 17, 2019.
About Linaclotide
Linaclotide is a guanylate cyclase‐C (GC‐C) agonist that binds to the GC-C receptor locally, within the intestinal epithelium.
Linaclotide is marketed by Ironwood and Allergan plc in the United States as LINZESS® and is indicated for the treatment of adults
with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), with greater than 2 million
unique patients in the United States having filled approximately 10 million linaclotide prescriptions since launch, according to
IQVIA. In Europe, Allergan markets linaclotide under the brand name CONSTELLA® for the treatment of adults with moderate to severe
IBS-C. In Japan, Ironwood's partner Astellas markets linaclotide under the brand name LINZESS for the treatment of adults with
IBS-C. Ironwood also has partnered with AstraZeneca for development and commercialization of linaclotide in China, Hong Kong and
Macau, and with Allergan for development and commercialization of linaclotide in all other territories worldwide.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a
difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two
innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome
with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine
oxidase inhibitor (XOI), or as a fixed-dose combination with allopurinol, for the treatment of hyperuricemia associated with gout.
We are also advancing a pipeline of innovative product candidates in areas of significant unmet need, including uncontrolled
gastroesophageal reflux disease, diabetic nephropathy, heart failure with preserved ejection fraction, achalasia and sickle cell
disease. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both
these locations.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on
developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products
for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power
ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website at www.Allergan.com. For more information, visit Allergan's website at www.Allergan.com.
LINZESS® and CONSTELLA® are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to in this
press release are the property of their respective owners. All rights reserved.
Forward-Looking Statement
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these
forward-looking statements, including statements about the resolution of patent litigation with Aurobindo Pharma and all related
settlement terms, including the date of generic entry and the potential for earlier generic entry under certain limited
circumstances; the dismissal of all Aurobindo Pharma Hatch-Waxman litigation regarding LINZESS; the submission of the settlement
agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review; the coverage, strength and extent of
the intellectual property covering LINZESS; and our confidence in the product’s market leadership and strength of its growth
trajectory. Each forward‐looking statement is subject to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to decisions
by regulatory and judicial authorities; competition and future business decisions made by us, as well as our competitors or
potential competitors; the risk that we may never get sufficient patent protection for linaclotide or that we are not able to
successfully protect such patents; the risk that we lose, or settle on less favorable terms, other linaclotide ANDA litigation, or
that other ANDA filers enter the market earlier than August 5, 2030, as well as any other potential settlements; developments in
the intellectual property landscape; and the risks listed under the heading "Risk Factors" and elsewhere in Ironwood's Annual
Report on Form 10-K for the year ended December 31, 2017, Allergan's Annual Report on Form 10-K for the year
ended December 31, 2017 and in the subsequent SEC filings of each company. These forward-looking statements
(except as otherwise noted) speak only as of the date of this press release, and Ironwood and Allergan undertake no
obligation to update these forward-looking statements.
Allergan Global Corporate Media Relations
Amy Rose, 862-289-3072
or
Allergan U.S. Product Relations
Fran DeSena, 201-427-8762
or
Allergan Investor Relations
Daphne Karydas, 862-261-7558
or
Ironwood Investor and Media Relations
Meredith Kaya, 617-374-5082
mkaya@ironwoodpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180503006491/en/